<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Esophageal Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (BA) develops through a multistage process, which is associated with the transcriptional silencing of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-suppressor genes by promoter CpG island hypermethylation </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we explored the promoter hypermethylation and protein expression of proapoptotic <z:hpo ids='HP_0011420'>death</z:hpo>-associated protein kinase (DAPK) during the multistep Barrett's <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> cascade </plain></SENT>
<SENT sid="2" pm="."><plain>Early BA and paired samples of <z:e sem="disease" ids="C0850639" disease_type="Neoplastic Process" abbrv="">premalignant lesions</z:e> of 61 patients were analyzed by methylation-specific polymerase chain reaction and immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>For the association of clinicopathological markers and protein expression, an immunohistochemical tissue microarray analysis of 66 additional BAs of advanced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stages was performed </plain></SENT>
<SENT sid="4" pm="."><plain>Hypermethylation of DAPK promoter was detected in 20% of <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa, 50% of Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, 53% of <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and 60% of <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, and resulted in a marked decrease in DAPK protein expression (P &lt; .01) </plain></SENT>
<SENT sid="5" pm="."><plain>The loss of DAPK protein was significantly associated with advanced depth of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invasion and advanced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stages (P &lt; .001) </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, the severity of reflux <z:hpo ids='HP_0100633'>esophagitis</z:hpo> correlated significantly with the hypermethylation rate of the DAPK promoter (P &lt; .003) </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, we consider DAPK inactivation by promoter hypermethylation as an early event in Barrett's <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> and suggest that a decreased protein expression of DAPK likely plays a role in the development and progression of BA </plain></SENT>
</text></document>